# Safety Study of Increasing Doses of CKD-516 in Patients With Advanced Solid Cancers

> **NCT01028859** · PHASE1 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 30 (estimated)

## Conditions studied

- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** CKD-516 inj

## Key facts

- **NCT ID:** NCT01028859
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2011-04
- **Final completion:** 2011-04
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2011-12-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01028859

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01028859, "Safety Study of Increasing Doses of CKD-516 in Patients With Advanced Solid Cancers". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01028859. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*